EUCTR2013-003269-33-BG进行中（未招募）1 期
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 552
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age and weight range as defined in the protocol.
- •Documented Physician-diagnosed asthma in line with the protocol requirements.
- •Subjects must have received a physician-prescribed asthma controller
- •regimen as outlined in the protocol.
- •Able to meet the pulmonary function requirements and other defined asthma metrics/measures as outlined in the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 510
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •Established diagnosis of occupational asthma.
- •Current smokers or subjects with a smoking history of = 10 pack years.
- •Any concomitant respiratory disease, including acute upper or lower respiratory infections.
- •Known history of active tuberculosis (TB).
- •Receipt of any marketed or investigational biologic agent within 4 months or 5 half lives prior to Visit 1 (Week 5), whichever is longer.
研究者
相似试验
进行中（未招募）
不适用
An Effectiveness and Safety Study of Inhaled JNJ 49095397 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.Moderate to Severe Chronic Obstructive PulmonaryDiseaseMedDRA version: 16.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-005184-27-HUJanssen-Cilag International NV200
进行中（未招募）
1 期
A study to evaluate the saftey and efficacy of KZR-616 for the tretament of patients with active inflammations of the muscle and the skin (rheumatic disease)EUCTR2019-002605-22-CZKezar Life Sciences, Inc.24
进行中（未招募）
1 期
Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarkers in Adults with Neuromuscular DiseaseBecker Muscular Dystrophy, McArdle Disease, Limb-Girdle Muscular DystrophyMedDRA version: 20.0Level: PTClassification code: 10059117Term: Becker's muscular dystrophy Class: 100000004850MedDRA version: 20.0Level: LLTClassification code: 10026970Term: McArdles disease Class: 10010331MedDRA version: 20.0Level: PTClassification code: 10028356Term: Muscular dystrophy Class: 100000004850CTIS2022-500215-39-00Edgewise Therapeutics Inc.21
进行中（未招募）
1 期
A clinical trial to investigate the effects of MEDI9929, a drug used in clinical research, in adults with uncontrolled, severe asthma, a disease that causes variable and recurring inflammation of the airways leading to difficulty in breathing.AsthmaEUCTR2013-003269-33-HUMedImmune LLC(a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA )552
进行中（未招募）
不适用
An Effectiveness and Safety Study of Inhaled JNJ 49095397 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.EUCTR2012-005184-27-ROJanssen-Cilag International NV200